Ottawa, ON – Innovative Medicines Canada (IMC) welcomes the new leadership of the Patented Medicine Prices Review Board (PMPRB) with the appointment of Thomas Digby as Chair.
IMC encourages the PMPRB to engage with health and life science stakeholders. We look forward to working with Mr. Digby and his PMPRB Board colleagues to ensure that Canadians have access to new medicines when they need them.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 50 companies who invest nearly $1.4 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
– 30 –
For further information:
Director, Media Relations & Content
E-mail: [email protected]